ECCO 2023

• La nutrition entérale exclusive est le gold standard pour induire la rémission au cours de la maladie de Crohn pédiatrique Luba Plotkin (Jerusalem, ISRAEL) - OP34 Enteral Nutrition Compared with Steroids in Children with Crohn’s Disease – In Israel: a nationwide study from the epi-IIRN
• Ustekinumab vs anti-TNF dans la maladie de Crohn : Résultats à 2 ans de l’étude prospective observationnelle RUN-CD B. Bokemeyer, Allemagne. OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
• Peut-on arrêter les anti-TNF lors d’une combothérapie sans risque de récidive ? Maria Chaparro - Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
• L’Upacitinib dans la maladie de Crohn, effet de l’exposition à une biothérapie Laurent Peyrin-Biroulet - Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
• Découverte de MICI lors d’examen de dépistage Eduard Brunet - Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
• Les biothérapies n’augmentent pas le risque de complication post opératoire au cours de la maladie de Crohn Mathurin FUMERY (Amiens, FRANCE) - DOP 89 Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide study
• La chirurgie : une alternative aux anti-TNF au diagnostic de la maladie de Crohn iléocæcale ? Manasi Agrawal (Copenhagen, Danemark) - OP11 Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved longterm outcomes compared to anti-tumor necrosis factor therapy: a population-based study.
• Pronostic à long-terme après une chirurgie précoce au cours de la maladie de Crohn Nathan Grellier (Paris) - DOP10 Early intestinal resection in Crohn’s Disease is not associated with severe long-term disease course
• Le vedolizumab chez les patients avec pochite chronique Jairath Vipul - Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
• Etude de cohorte prospective sur 40 ans: incidence de la colectomie dans la RCH Peter.L. Lakatos PhD, Mcgill University Health Center, IBD Centre, Montréal, Canada, Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020
• Une consultation unique de transition pédiatrie adulte réduit le risque de poussée dans l’année Cristina Rubín De Célix (Alicante, Espagne) - OP27 Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
• Contraception chez les femmes avec MICI aux US Erica Brenner - Contraceptive method use according to Inflammatory Bowel Disease status among young women in the United States
• Résultats de l’étude REPREVIO : Le Vedolizumab prévient-il la récidive post opératoire dans la maladie de Crohn ? Geert D'Haens, Amsterdam University Medical Centres, Gastroenterology, Amsterdam, The Netherlands,Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
• L’antibiothérapie, facteur de risque de MICI même chez l’adulte Adam Faye - Antibiotic Use as a Risk Factor for Inflammatory Bowel Disease Across the Ages: A PopulationBased Cohort Study
• La rémission durable après résection iléocaecale dans la maladie de Crohn est-elle possible ? Résultats au long court de la cohorte du GETAID chirurgie S. Abdalla, Le Kremlin-Bicetre, France; DOP77Is durable remission achievable after ileocolic resection for Crohn's disease? Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie
• L’échographie dans la maladie de Crohn : outil validé ? Barbara Morao, Hospital Beatriz Ângelo, Gastroenterology, Lisbon, Portugal,Intestinal ultrasound correlates with colonoscopy and biomarkers, and can be used in a tight monitoring approach to assess response to therapy in Crohn's disease: a multicentre prospective study
• Risque de complications néphrologiques et MICI Yuanhang Yang (Stockholm, Sweden) - OP07 Absolute and relative risks of kidney and urological complications in patients with Inflammatory Bowel Disease
• Upadacitinib dans la RCH modérée à sévère : efficacité prouvée même après anti-TNF ! Séverine Vermeire, University Hospital Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium; Abstract citation ID: jjac190.0004, OP04, Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti- TNF-inadequate response patients